ACS Central Science · 2016 · 396 citations · 23 references
Life SciencesBiochemistryMolecular BiologyMolecular OncologyProtein EngineeringSignal TransductionEnzyme InhibitionLinker ChemistryMacromolecular AssemblyProtein DegradationProtein TargetingTetrazine LigationBifunctional MoleculesCovalent InhibitionE3 Ubiquitin Ligase Substrate RecognitionMolecular Self-assemblyProtein Proteolysis EngineeringTargeted Protein DegradationUbiquitin-mediated DegradationUbiquitin-mediated Proteolysis
High Resolution Image Download MS PowerPoint Slide Selective degradation of proteins by proteolysis targeting chimeras (PROTACs) offers a promising potential alternative to protein inhibition for therapeutic intervention. Current PROTAC molecules incorporate a ligand for the target protein, a linker, and an E3 ubiquitin ligase recruiting group, which bring together target protein and ubiquitinating machinery. Such hetero-bifunctional molecules require significant linker optimization and possess high molecular weight, which can limit cellular permeation, solubility, and other drug-like properties. We show here that the hetero-bifunctional molecule can be formed intracellularly by bio-orthogonal click combination of two smaller precursors. We designed a tetrazine tagged thalidomide derivative which reacts rapidly with a trans -cyclo-octene tagged ligand of the target protein in cells to form a cereblon E3 ligase recruiting PROTAC molecule. The in-cell click-formed proteolysis targeting chimeras (CLIPTACs) were successfully used to degrade two key oncology targets, BRD4 and ERK1/2. ERK1/2 degradation was achieved using a CLIPTAC based on a covalent inhibitor. We expect this approach to be readily extendable to other inhibitor-protein systems because the tagged E3 ligase recruiter is capable of undergoing the click reaction with a suitably tagged ligand of any protein of interest to elicit its degradation.
23
Kathleen M. Sakamoto, Kyung B. Kim, Akiko Kumagai et al. · Proceedings of the National Academy of Sciences · 2001 · 2.5K citations · Full text
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito, Hideki Ando, Takayuki Suzuki et al. · Science · 2010 · 2.1K citations
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter, Dennis L. Buckley, Joshiawa Paulk et al. · Science · 2015 · 1.7K citations
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P. Bondeson, Alina Mares, Ian E. Smith et al. · Nature Chemical Biology · 2015 · 1.3K citations · Full text